공시 • May 13
Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026 Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026. 공시 • Apr 01
Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026 공시 • Dec 19
Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026 Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026 공시 • Sep 29
Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53. 공시 • Sep 11
Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025 Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025 공시 • May 31
Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025 Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025 공시 • Apr 11
Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025 Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025. 공시 • Mar 26
Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million. Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction.
Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc.
Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025. 공시 • Mar 25
Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025 공시 • Feb 26
Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million. Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock. 공시 • Dec 22
Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million. Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to 공시 • Nov 30
Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025 Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025 공시 • Sep 03
Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024 Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024 공시 • Jun 26
Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024 Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024 공시 • May 16
Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024 Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024. 공시 • Mar 03
Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024 Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024 공시 • Dec 08
Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024 Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024 공시 • Sep 19
Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD) Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD) 공시 • Aug 30
Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023 Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023 공시 • May 28
Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023 Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023 공시 • May 12
Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023 Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023. 공시 • Dec 28
Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023 Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023 
